First Trust NYSE Arca Biotechnology Index Fund FBT
275.07 USD +3.48 (+1.28%)
At closeNov 11, 2026, 7:55 PM EST
272.66 -2.41 -0.88%
After hours · Nov 11, 7:55 PM ET
271.51 Day range 275.54
189.47 52-week range 283.21
- YTD
- +33.19%
- 1 year
- +36.21%
News
zacks.com Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? Making its debut on 06/19/2006, smart beta exchange traded fund First Trust NYSE Arca Biotechnology ETF (FBT) provides investors broad exposure to the Health Care ETFs category of the market.
fool.com Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT? One fund holds about 60 drug companies at a lower fee. The other holds 30 biotech names and has a stronger long-term record. Either way, expect some volatility.
fool.com Which Is the Better Buy: iShares' Pharma ETF IHE or First Trust's Biotech Fund FBT? iShares U.S. Pharmaceuticals ETF has a lower expense ratio than the First Trust NYSE Arca Biotechnology Index Fund. First Trust NYSE Arca Biotechnology Index Fund maintains a more concentrated…
zacks.com Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange traded fund…
zacks.com ETFs That You May Consider Amid a Strengthening Biotech Outlook Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.
fool.com Which Healthcare ETF Is the Better Buy: Simplify's Mission-Driven PINK or First Trust's Biotech FBT? First Trust NYSE Arca Biotechnology Index Fund tracks a concentrated index of 30 biotech stocks, while Simplify Health Care ETF is an actively managed fund with broader healthcare exposure. Simplify…
fool.com Which Healthcare ETF Is the Better Buy: Invesco’s Broad RSPH or First Trust’s Biotech FBT? FBT has outperformed RSPH by a wide margin recently. The question is whether you want to own the fund that won last year or the one built to hold up over many years.
fool.com Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT? iShares Global Healthcare ETF offers a lower expense ratio and broader sector exposure than First Trust NYSE Arca Biotechnology Index Fund. First Trust NYSE Arca Biotechnology Index Fund focuses…
fool.com Better Biotechnology ETF: First Trust FBT vs. VanEck BBH The First Trust NYSE Arca Biotechnology Index Fund has outperformed the VanEck Biotech ETF on a one-year basis and over the last five years. The VanEck Biotech ETF offers a lower expense ratio of…
benzinga.com Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
zacks.com Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.
zacks.com Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? A smart beta exchange traded fund, the First Trust NYSE Arca Biotechnology ETF (FBT) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market.
fool.com Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT? One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.
zacks.com Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? Launched on June 19, 2006, the First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of…
fool.com XBI vs. FBT: Broad Biotech Exposure or Concentrated Bets? State Street SPDR S&P Biotech ETF carries a lower expense ratio of 0.35% compared to First Trust NYSE Arca Biotechnology Index Fund. FBT maintains a highly concentrated portfolio of only 30 holdings,…
fool.com IYH vs. FBT: Broad Healthcare ETF or Concentrated Biotech Play? The iShares U.S. Healthcare ETF provides broad sector exposure with 100 holdings, while the First Trust NYSE Arca Biotechnology Index Fund focuses on a concentrated basket of 30 biotech stocks. The…
247wallst.com FBT and IBB Are Not the Same Biotech Bet, and 5 Years of Returns Prove It Biotech investors picking between the First Trust NYSE Arca Biotechnology Index Fund (NYSEARCA:FBT) and the iShares Biotechnology ETF (NASDAQ:IBB) often treat them as interchangeable proxies for the…
fool.com Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT? FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.
fool.com Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT? iShares Global Healthcare ETF provides broad exposure to 110 global stocks while First Trust NYSE Arca Biotechnology Index Fund concentrates on 30 biotech positions. iShares Global Healthcare ETF…
fool.com Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV? FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.
fool.com Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance? First Trust NYSE Arca Biotechnology Index Fund offers a more concentrated portfolio with only 30 holdings compared to the 248 positions in iShares Biotechnology ETF iShares Biotechnology ETF is the…
benzinga.com Why Is Natera Stock Gaining Tuesday? Natera (NTRA) stock rallies following a key NCCN guideline update for Signatera. Also, check out the full NTRA stock analysis.
benzinga.com Moderna's Legal Hit Steals Spotlight From Strong Sales MRNA revenue hits $389M, beating Wall Street estimates. Despite a Q1 loss, Moderna eyes 10% growth and new flu vaccine approvals in 2026.
benzinga.com FDA Makes U-Turn Again On Moderna New Flu Vaccine Review, Stock Soars Moderna's mRNA-1010 flu vaccine clears FDA review, with stock rising ahead of major approvals.
benzinga.com Moderna, Mexico Partner To Boost Local Vaccine Production Moderna signs a long-term deal with Mexico to build local mRNA production, transfer technology, and supply up to 10 million COVID vaccine doses for the 2025–2026 campaign.
benzinga.com Moderna (MRNA) Stock Pulls Back After Recent Strength Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.
benzinga.com Moderna Stock Explodes To New 52-Week High: What's Driving The Action? Moderna Inc (NASDAQ: MRNA) stock is trading higher Thursday morning, hitting a new 52-week high after new cancer trial data.
benzinga.com Illumina Gets Medicare Boost for Cancer Test, Shares Climb Illumina shares rose after Medicare approved reimbursement for its FDA-approved cancer test, a move expected to drive growth.
benzinga.com POET Technologies Lands $5 Million Order As AI Demand Surges POET Tech received $5M order for POET Infinity engines. They cater to AI networks, data centers. CEO touts tech & customer trust.
benzinga.com NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH.
benzinga.com Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval…
benzinga.com Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug.
benzinga.com New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this…
benzinga.com Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating…
benzinga.com FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits - benzinga.com US Judge Weighs Nationwide Ban On Abortion Pills U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is…
benzinga.com FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug' - benzinga.com Q2 Growth 'Nothing Short Of Virtuous': Economist The coronavirus pandemic that began in 2020 and is persisting today has led many investors to hold poor market expectations. But maybe they shouldn’t be so pessimistic.
- benzinga.com 5 Top ETFs With Exposure To Biogen For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA.
benzinga.com 3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a- benzinga.com Election History Says Buy Biotech Dip Biotechnology exchange-traded funds were hot until they weren't. History indicates recent weakness in the previously high-flying group be a symptom of election year jitters and investors shouldn't…
- benzinga.com Post-Pandemic Stars Could Align For This Biotech ETF These days, it's not hard to find winners among health care exchange-traded funds and that's true of both established and rookie players.
- benzinga.com 3 ETFs Chock Full Of Companies With Negative Earnings Revisions
- benzinga.com Once Beloved Momentum ETF Loses Its Momo
- benzinga.com Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech
- benzinga.com Clinton's Proposal To Combat Drug Price Hikes
benzinga.com Government Study: Cellphone Radiation Linked To Cancer - benzinga.com Focus 5 ETF Makes Another Change
- benzinga.com Focus 5 ETF Gets A Dynamic Counterpart
- benzinga.com Popular ETF Of ETFs Gets Defensive After Market Slide